8 results on '"Bolwell, Brian J."'
Search Results
2. Prospective Clinical Study of Precision Oncology in Solid Tumors.
- Author
-
Sohal, Davendra P. S., Rini, Brian I., Khorana, Alok A., Dreicer, Robert, Abraham, Jame, Procop, Gary W., Saunthararajah, Yogen, Pennell, Nathan A., Stevenson, James P., Pelley, Robert, Estfan, Bassam, Shepard, Dale, Funchain, Pauline, Elson, Paul, Adelstein, David J., and Bolwell, Brian J.
- Subjects
DNA analysis ,ANTINEOPLASTIC agents ,BREAST tumors ,DRUG therapy ,COLON tumors ,GENES ,LONGITUDINAL method ,ONCOLOGY ,PANCREATIC tumors ,RECTUM tumors ,TUMORS ,BILE duct tumors ,PILOT projects ,GENE expression profiling ,SEQUENCE analysis ,PHARMACODYNAMICS - Abstract
Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We conducted a prospective study in 250 patients with select solid tumors at the Cleveland Clinic. Eligibility required histopathologic diagnosis, age of 18 years or older, Eastern Cooperative Oncology Group performance status 0-2, and written informed consent. Tumors were sequenced using FoundationOne (Cambridge, MA). Results were reviewed at the Cleveland Clinic Genomics Tumor Board. Outcomes included feasibility and clinical impact. Colorectal (25%), breast (18%), lung (13%), and pancreatobiliary (13%) cancers were the most common diagnoses. Median time from consent to result was 25 days (range = 3-140). Of 223 evaluable samples, 49% (n = 109) of patients were recommended a specific therapy, but only 11% (n = 24) received such therapy: 12 on clinical trials, nine off-label, three on-label. Lack of clinical trial access (n = 49) and clinical deterioration (n = 29) were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia
- Author
-
Copelan, Edward A., Crilley, Pamela Ann, Szer, Jeffrey, Dodds, Anthony J., Stevenson, Dustin, Phillips, Gary, Elder, Patrick, Nivison-Smith, Ian, Avalos, Belinda R., Penza, Sam, Topolsky, David, Sobecks, Ronald, Kalaycio, Matt, and Bolwell, Brian J.
- Subjects
- *
MORTALITY , *DISEASE relapse , *HLA histocompatibility antigens , *STEM cell transplantation , *DRUG therapy , *HEMATOPOIETIC stem cells , *TREATMENT of chronic myeloid leukemia - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for chronic myelogenous leukemia (CML). Failure, because of relapse or nonrelapse mortality (NRM), generally occurs within 3 years of transplantation, but large studies with long-term follow-up are limited. We present mature results in 335 patients with CML who underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings following busulfan and cyclophosphamide (BU/Cy2). Two hundred twenty-nine were in chronic phase (CP) and 106 in accelerated or blastic phase at transplantation. Median follow-up exceeded 14 years. The estimated probability of 18-year leukemia-free survival (LFS) for CP patients was 55.6% and for those beyond CP, 10.5%. Of 182 patients who survived leukemia-free at 3 years, the estimated probability of LFS at 18 years was 61.9%. Late relapse (P = .039) and late NRM (P = .008) occurred at higher rates in patients beyond CP at transplantation. There was no plateau in LFS. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
4. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
- Author
-
Hari, Parameswaran, Carreras, Jeanette, Zhang, Mei-Jie, Gale, Robert Peter, Bolwell, Brian J., Bredeson, Christopher N., Burns, Linda J., Cairo, Mitchell S., Freytes, César O., Goldstein, Steven C., Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Schouten, Harry C., Slavin, Shimon, Vose, Julie M., Lazarus, Hillard M., and van Besien, Koen
- Subjects
- *
STEM cells , *CELLULAR therapy , *DRUG therapy , *BLOOD cells - Abstract
Abstract: Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem cell transplantation (HSCT) in follicular lymphoma (FL). We compared traditional myeloablative conditioning regimens to RIC in FL. Outcomes of HLA-identical sibling HSCT for FL in 208 recipients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1997 and 2002 were studied. Conditioning regimens were categorized as myeloablative (N = 120) or RIC (N = 88). Use of RIC regimens increased from <10% of transplants in 1997 to >80% in 2002 signaling a major shift in practice. Patients receiving RIC were older and had a longer interval from diagnosis to transplant. These differences did not correlate with outcomes. Median follow-up of survivors was 50 months (4-96 months) after myeloablative conditioning versus 35 months (4-82 months) after RIC (P < .001). At 3 years, overall survival (OS) for the myeloablative and RIC cohorts were 71 (63%-79%) and 62 (51%-72%; P = .15) and progression free survival (PFS), 67 (58%-75%) and 55 (44%-65%; P = .07), respectively. Lower Karnofsky performance score (KPS) and resistance to chemotherapy were associated with higher treatment-related mortality (TRM) and lower OS and PFS. On multivariate analysis, an increased risk of lymphoma progression after RIC was observed (relative risk = 2.97, P = .04). RIC has become the de facto standard in allogeneic HSCT for FL, and appears to result in similar long-term outcomes. Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
5. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR
- Author
-
Schlenk, Richard F., Pasquini, Marcelo C., Pérez, Waleska S., Zhang, Mei-Jie, Krauter, Jürgen, Antin, Joseph H., Bashey, Asad, Bolwell, Brian J., Büchner, Thomas, Cahn, Jean-Yves, Cairo, Mitchell S., Copelan, Edward A., Cutler, Corey S., Döhner, Hartmut, Gale, Robert Peter, Ilhan, Osman, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., and Marks, David I.
- Subjects
- *
CELLULAR therapy , *CELL transplantation , *HEMATOPOIETIC stem cells , *DRUG therapy - Abstract
Abstract: We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission. Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials. Characteristics of the cohorts were similar except that chemotherapy recipients were significantly older. To adjust for time to treatment bias, outcomes were compared using left-truncated Cox regression models. Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2). Loss of sex chromosomes (LOS) in addition to t(8;21) had a negative impact on overall survival (OS) in patients receiving chemotherapy. Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05, P = .02), whereas patients with LOS had similar survival regardless of postremission therapy. In both cohorts, white blood cell count (WBC) at diagnosis >25 × 109/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01). In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM. In the group without LOS, survival after chemotherapy was far superior to HCT. These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
6. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
- Author
-
Giles, Francis J., Rodriguez, Roberto, Weisdorf, Daniel, Wingard, John R., Martin, Paul J., Fleming, Thomas R., Goldberg, Stuart L., Anaissie, Elias J., Bolwell, Brian J., Chao, Nelson J., Shea, Thomas C., Brunvand, Mark M., Vaughan, William, Petersen, Finn, Schubert, Mark, Lazarus, Hillard M., Maziarz, Richard T., Silverman, Margarida, Beveridge, Roy A., and Redman, Rebecca
- Subjects
- *
PLACEBOS , *STOMATITIS , *DRUG therapy , *PATHOLOGICAL physiology - Abstract
The invasion and colonization of oral cavity mucosal tissues by microflora may contribute to the pathophysiology of ulcerative oral mucositis (UOM). Iseganan is an analog of protegrin-1, a naturally occurring peptide with broad-spectrum microbicidal activity. A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of iseganan in preventing UOM after stomatotoxic therapy.Patients received an oral rinse, consisting of iseganan 9 mg or placebo, to be swished/swallowed six times daily, starting with stomatotoxic therapy and continuing up to 21 days. Patients were assessed for stomatitis and UOM, and administered a questionnaire evaluating mouth pain and difficulty swallowing thrice weekly. The primary study efficacy endpoint was the proportion of patients who did not have peak stomatitis NCI-CTC grade ≥2.Between November 2001 and June 2002, 502 patients were randomized to receive iseganan (251) or placebo (251). Equivalent numbers of patients in both cohorts received bone marrow or peripheral blood allogeneic or autologous stem cell transplantation (SCT). Forty-three percent and 37% of iseganan and placebo patients, respectively, did not have peak stomatitis grade =2 (
P=0.182 ). There was no significant difference between the cohorts in stomatitis severity, incidence of UOM, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence.A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
7. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial
- Author
-
Stiff, Patrick J., Unger, Joseph M., Forman, Stephen J., McCall, Anne R., LeBlanc, Michael, Nademanee, Auayporn P., Bolwell, Brian J., and Fisher, Richard I.
- Subjects
- *
IRRADIATION , *BONE marrow transplantation , *DRUG therapy , *HODGKIN'S disease - Abstract
Several single-institution pilot studies have suggested that augmented preparative regimens, including those containing total body irradiation combined with an autologous bone marrow transplantation, are superior to standard regimens for the treatment of relapsed or refractory Hodgkin disease. On the basis of these data, we undertook, in the cooperative group setting, a phase II trial of augmented preparative regimens for patients experiencing treatment failure with conventional chemotherapy. Eighty-one patients with either sensitive or refractory (induction failures or chemoresistant) relapse received etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either total body irradiation (12 Gy) or, if previously irradiated, carmustine (15 mg/kg), followed by an autologous bone marrow transplantation. Progression-free (PFS) and overall (OS) survival were estimated, and a Cox regression model was used to assess potential prognostic variables. The 5-year PFS and OS for the 74 eligible patients treated at 20 Southwest Oncology Group centers were 41% (95% confidence interval [CI], 29%–53%) and 54% (95% CI, 43%–65%), respectively, despite a median remission after initial chemotherapy of only 6 months. The 3-year OS for those whose induction therapy failed was 72% (95% CI, 52%–93%). There was 1 (1.4%) early treatment-related death, 2 late deaths due to lung toxicity, and only 1 death due to myelodysplasia. There were no differences in PFS or OS on the basis of regimen or chemosensitivity. A Cox prognostic factor analysis determined that >2 prior regimens, relapse in a radiated field, and extranodal disease were adverse prognostic factors. Among the 46 patients who received prior radiotherapy, the 5-year OS was 38% (95% CI, 14%–61%) for patients with 2 or 3 adverse factors, versus 60% (95% CI, 42%–78%) for those with 0 factors or 1 adverse factor. Augmented preparative regimens seem promising for the treatment of relapsed or refractory Hodgkin disease, without an increase in regimen-related mortality. A poor-prognosis group was identified that should be treated with novel therapies. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
8. Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR
- Author
-
Hale, Gregory A., Shrestha, Smriti, Le-Rademacher, Jennifer, Burns, Linda J., Gibson, John, Inwards, David J., Freytes, Cesar O., Bolwell, Brian J., Hsu, Jack W., Slavin, Shimon, Isola, Luis, Rizzieri, David A., Gale, Robert Peter, Laport, Ginna G., Montoto, Silvia, Lazarus, Hillard M., and Hari, Parameswaran N.
- Subjects
- *
DRUG therapy , *HEMATOPOIETIC stem cell transplantation , *LYMPHOMAS , *MORTALITY , *HISTOPATHOLOGY , *GLOBULINS - Abstract
We analyzed the outcomes of 248 (61% male) adult recipients of HLA-matched unrelated and HLA-mismatched related donor hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma (NHL) after reduced or lower intensity conditioning (RIC), reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1997 to 2004. Median age was 52 (range: 18-72 years); 31% had a Karnofsky performance score <90. Follicular NHL (43%) was the major histology. Incidence of grades II-IV acute graft-versus-host disease (aGVHD) was 43% at 100 days; and chronic GVHD (cGVHD) was 44% at 3 years. Treatment-related mortality (TRM) at 100 days was 24%. Three-year overall survival (OS) and progression-free survival (PFS) were 41% and 32%, respectively. In multivariate analysis, use of antithymocyte globulin (ATG) and HLA mismatch were associated with increased TRM. High-grade histology, ATG use, and chemotherapy resistance were associated with lower PFS. Older age, shorter interval from diagnosis to HCT, non–total body irridiation (TBI) conditioning regimens, ex vivo T cell depletion, and HLA-mismatched unrelated donors were associated with mortality. GVHD did not influence relapse or PFS. Older age, aggressive histology, and chemotherapy resistance correlated with poorer survival. For selected patients with NHL, lack of an available sibling donor should not be a barrier to allogeneic HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.